Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 9 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-containing chemotherapy and one programmed death-ligand 1 checkpoint inhibitor	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Cabozantinib for Hepatocellular Carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2017	View \| Download
Cabozantinib for treating differentiated thyroid cancer	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Differentiated thyroid cancer (DTC)	Head and Neck Cancer	2021	View \| Download
Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications